Related Experiment Videos
[Vitamin D therapy in predialysis renal failure]
1Department of Nephrology, Musashino Red Cross Hospital.
Clinical Calcium
|December 4, 2004
Summary
Vitamin D therapy can help predialysis patients with secondary hyperparathyroidism. Careful monitoring and small starting doses of calcitriol or alfacalcidol are recommended to manage vitamin D deficiency and prevent kidney function decline.
Area of Science:
- Nephrology
- Endocrinology
- Nutritional Science
Background:
- Secondary hyperparathyroidism is common in predialysis renal failure patients.
- Vitamin D deficiency contributes to secondary hyperparathyroidism and renal osteodystrophy (osteitis fibrosa).
Purpose of the Study:
- To outline the role of vitamin D therapy in managing secondary hyperparathyroidism in predialysis patients.
- To recommend appropriate therapeutic strategies for vitamin D supplementation.
Main Methods:
- Review of current clinical guidelines and evidence regarding vitamin D therapy in predialysis renal failure.
- Monitoring of serum calcium, phosphorus, and parathyroid hormone (PTH) levels.
Main Results:
- Vitamin D therapy effectively suppresses PTH levels.
- Vitamin D therapy ameliorates osteitis fibrosa, a complication of renal osteodystrophy.
Conclusions:
- Vitamin D therapy is indicated for predialysis renal failure patients with vitamin D deficiency and secondary hyperparathyroidism.
- Initiating therapy with low doses of calcitriol or alfacalcidol (0.25 microg/day) is advised.
- Careful dose adjustment and monitoring of serum calcium, phosphorus, and PTH are crucial to prevent worsening renal function.